Department of Orthopaedic Surgery, School of Medicine, Kanazawa University, Kanazawa, Japan.
Department of Orthopaedic Surgery, School of Medicine, Kanazawa University, Kanazawa, Japan.
Knee. 2022 Oct;38:1-8. doi: 10.1016/j.knee.2022.06.001. Epub 2022 Jul 16.
In this study, we investigated newly developed ultrasound (US)-guided medial collateral ligament (MCL) bursa injection as a conservative therapy for symptomatic degenerative medial meniscal (MM) tears. We aimed to describe the anatomical target and precise technique of this injection, confirm its accuracy using fresh cadaveric knees, and then evaluate preliminary clinical outcomes.
Anatomical studies were performed on three fresh cadavers. For the clinical study, 50 patients with medial knee joint pain without knee osteoarthritis were treated with US-guided MCL bursa injection. Severity of pain was assessed pre-injection, and 1 week and 4 weeks post-injection using a 0-10 numerical rating scale (NRS). Clinical success was defined as a full return to daily activities. All patients underwent magnetic resonance imaging (MRI) within 1 week of the first injection. Patients who underwent surgery within 12 months of the first injection were investigated as clinically unsuccessful cases, and MRI and arthroscopic findings were examined.
Compared with pre-injection (6.8 ± 1.2), the average NRS score was significantly lower at 1 week (1.8 ± 2.0) and at 4 weeks (1.5 ± 1.7) post-injection (both P < 0.01). The primary clinical success rate was 76.0%, and injection-related adverse events were not observed. Nine patients underwent surgery (arthroscopic surgery for degenerative flap tear (n = 7) and high tibial osteotomy for medial meniscus posterior root tear and proximal tibial malalignment (n = 2)).
US-guided MCL bursa injection is safe, reproducible, and effective for symptomatic MM degenerative tears. However, US-guided injections of the MCL bursa may be ineffective for flap tears and posterior root tears.
本研究旨在探讨新开发的超声(US)引导内侧副韧带(MCL)滑囊注射作为治疗症状性退行性内侧半月板(MM)撕裂的保守疗法。我们旨在描述该注射的解剖靶标和精确技术,使用新鲜的尸体膝关节确认其准确性,然后评估初步的临床结果。
对三个新鲜尸体进行解剖学研究。对于临床研究,对 50 例内侧膝关节疼痛但无膝骨关节炎的患者进行 US 引导的 MCL 滑囊注射。在注射前、注射后 1 周和 4 周使用 0-10 数字评分量表(NRS)评估疼痛严重程度。临床成功定义为完全恢复日常活动。所有患者在第一次注射后 1 周内进行磁共振成像(MRI)检查。在第一次注射后 12 个月内接受手术的患者被视为临床不成功病例,并对 MRI 和关节镜检查结果进行了调查。
与注射前(6.8±1.2)相比,注射后 1 周(1.8±2.0)和 4 周(1.5±1.7)的平均 NRS 评分显著降低(均 P<0.01)。主要临床成功率为 76.0%,未观察到与注射相关的不良反应。9 例患者接受了手术(关节镜手术治疗退行性瓣状撕裂(n=7)和高位胫骨截骨术治疗内侧半月板后根撕裂和胫骨近端对线不良(n=2))。
US 引导的 MCL 滑囊注射是一种安全、可重复、有效的治疗症状性 MM 退行性撕裂的方法。然而,US 引导的 MCL 滑囊注射可能对瓣状撕裂和后根撕裂无效。